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Abstract
The ability of liposomes bearing anti-HLA-DR FabP fragments to target cells expressing the human HLA-DR determinant
of the major histocompatibility complex class II (MHC-II) has been evaluated and compared to that of conventional
liposomes. Anti-HLA-DR immunoliposomes did not bind to HLA-DR-negative cells. In contrast, a high level of binding was
observed following incubation of immunoliposomes with cells bearing important levels of human HLA-DR. The
accumulation of conventional and murine anti-HLA-DR immunoliposomes in different tissues has been investigated
following a single subcutaneous injection given in the upper back of C3H mice. Anti-HLA-DR immunoliposomes resulted in
a much better accumulation in the cervical and brachial lymph nodes when compared to conventional liposomes. The
accumulation in the liver was similar for both liposomal preparations, whereas an approximately twofold decrease in
accumulation was observed for immunoliposomes in the spleen. Given that HLA-DR surface marker is expressed on
monocyte/macrophages and activated CD4+ T lymphocytes, the primary cellular reservoirs of the human immunodeficiency
virus (HIV), the use of liposomes bearing surface-attached anti-HLA-DR could constitute a convenient strategy to more
efficiently treat this debilitating retroviral disease. Moreover, the reported incorporation of high amounts of host-encoded
HLA-DR proteins by HIV particles renders the use of liposomes bearing anti-HLA-DR antibodies even more
attractive. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
It is now well-established that in the early stage of
human immunode¢ciency virus (HIV) infection and
throughout the clinical latent stage, HIV accumulates
and replicates actively in lymphoid organs despite a
low viral load in peripheral blood. It was shown that
the frequency of infected cells in lymph nodes was
5- to 10-fold higher than that in peripheral blood [1].
In addition, it was estimated that the number of viral
particles present in an entire lymph node could be as
high as 1.2U109 particles per cm3 [2]. The high viral
load observed in the lymphoid tissues was reported
to be partly associated with trapped HIV particles on
the follicular dendritic cells (FDC) located in the
germinal centers [1,3,4]. In addition to the extracel-
lular localization of HIV in interdendritic spaces of
germinal centers, viral particles were also found with-
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in the endosomal and cytoplasm compartments of
FDC [5]. Moreover, viral particles bound onto the
FDC remained highly infectious for CD4+ T cells
despite the presence of neutralizing antibodies on
their surface [6,7]. Over the course of HIV infection,
the FDC network was shown to be gradually dis-
rupted and ultimately destroyed. The incapacity of
FDC to retain HIV particles in advanced stages of
the disease has been postulated to contribute to the
increased viral burden in the periphery [8].
As the microenvironment of lymphoid tissues is
crucial for e¡ective immune responses, it is impor-
tant to decrease viral burden and inhibit virus repli-
cation at the earliest possible time after infection.
Three-drug treatment therapy markedly diminished
the number of HIV-1 RNA copies found in sec-
ondary lymphoid tissues such as the tonsils [2]. How-
ever, a few copies of HIV-1 RNA were still detect-
able and could thus represent a focus of infection
once the therapy is stopped due to the frequent tox-
icity seen in patients undergoing combined antiretro-
viral therapy. As suboptimal concentrations of drugs
within infected cells can potentially lead to the devel-
opment of resistance, the delivery of high drug con-
centrations into HIV reservoirs could also reduce the
frequency of resistance. Therefore, strategies aimed
at reaching therapeutic levels of drugs into the lym-
phoid organs should be developed to improve the
e⁄cacy and safety of antiretroviral agents.
As liposomes are naturally taken up by cells of the
mononuclear phagocytic system (MPS), liposome-
based therapy could represent a convenient approach
to improve the delivery of anti-HIV agents within
lymphoid tissues. In the past few years, liposomes
have received considerable interest for targeting
lymph nodes. The e¡ect of various parameters on
the lymphatic uptake of liposomes after subcutane-
ous injection has been recently investigated in rats
[9^11]. Decisive factors in£uencing the lymphatic up-
take of liposomes include the anatomical site of in-
jection and the liposome size. Allen and co-workers
showed that liposomes bearing polyethyleneglycol
(PEG) chains, administered subcutaneously to mice,
were e⁄cient to deliver high levels of liposomes to
the lymph nodes [12]. On the other hand, liposomes
injected subcutaneously into the footpad of the hind-
leg of rats were very e⁄cient to target the regional
lymph nodes [13]. Moreover, we showed that 112 nm
conventional liposomes allowed e⁄cient targeting of
lymph nodes and macrophage-rich tissues (spleen
and liver) for up to at least 24 h after the adminis-
tration of a single intravenous injection in mice [14].
In addition, the accumulation of liposomal foscarnet
in the lymph nodes of rats was found to be eight
times greater than that of free foscarnet [15].
Considering that HIV accumulates and replicates
actively within lymphoid tissues, any strategy that
will decrease viral stores in these tissues might be
bene¢cial to the infected host. As the human HLA-
DR determinant of the major histocompatibility
complex class II (MHC-II) is abundantly expressed
on antigen presenting cells such as monocyte/macro-
phages and FDC, liposomes bearing surface-attached
anti-HLA-DR constitute a logical strategy to target
such viral reservoirs. In this study, the ability anti-
HLA-DR immunoliposomes to bind to cells express-
ing HLA-DR has been evaluated and compared to
that of conventional liposomes. The accumulation of
conventional and murine anti-HLA-DR immuno-
liposomes within lymphoid tissues has also been
investigated following a single subcutaneous injection
given in the upper back of C3H mice.
2. Materials and methods
2.1. Materials
Dipalmitoylphosphatidylcholine (DPPC) and di-
palmitoylphosphatidylglycerol (DPPG) were pur-
chased from Avanti Polar Lipids (Alabaster,
AL). N-(4-(p-maleimidophenyl)butyryl)-dipalmitoyl-
phosphatidylethanolamine (MPB-DPPE) was ob-
tained from Northern Lipids (Vancouver, BC).
[3H]Cholesterylhexadecylether was purchased from
NEN Life Science (Boston, MA). 1,1P-dioctadecyl-
3,3,3P,3P-tetramethylindocarbocyanine perchlorate
(DiI) was purchased from Molecular Probes (Eu-
gene, OR). Lysyl endopeptidase obtained from Ach-
romobacter lyticus was purchased from Wako Chem-
icals (Richmond, VA) and 2-mercaptoethylamine^
HCl was obtained from Pierce (Rockford, IL).
2.2. Preparation of antibodies
Hybridomas producing monoclonal antibodies di-
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rected against human (clone 2.06, IgG1) and murine
(clone Y-17, IgG2b) HLA-DR were obtained from
the American Type Culture Collection (ATCC;
Rockville, MD). Antibodies were isolated from as-
cites £uids of BALB/c mice and puri¢ed using a pro-
tein-G a⁄nity column according to manufacturer’s
instructions (Pharmacia, Baie d’Urfe¤, QC). The total
protein concentration in ascites was approximately
20 mg/ml and the speci¢c antibody concentration
was in the range of 1^5 mg/ml leading to a yield of
pure antibody of 5^25%. Antibodies were sterilized
on 0.22 Wm low binding protein ¢lters (Millipore,
Bedford, MA) and stored at 320‡C in phosphate
bu¡ered saline (PBS, pH 7.4). Purity of antibodies
was assessed by sodium dodecyl sulfate^polyacryl-
amide gel electrophoresis (SDS^PAGE) under non-
reducing conditions. The apparent molecular mass
was veri¢ed using BenchMarker prestained protein
ladder (GIBCO BRL, Grand Island, NY). Gel stain-
ing was performed with Coomassie brilliant blue
(Sigma, St. Louis, MO).
The immunoreactivity of 2.06 and Y-17 antibodies
was tested by £ow cytometry on RAJI cells (Human
Burkitt’s lymphoma, ATCC) and on freshly prepared
C3H mouse spleen cells, respectively. In brief, sus-
pension of cells (106 cells/ml) was incubated with
either 1 Wg of 2.06 or biotinylated-Y-17 antibodies.
After a 30-min incubation at 4‡C, cells were washed
three times with PBS and incubated with 1:50 £uo-
rescein isothiocyanate (FITC)-conjugated goat anti-
mouse IgG (Cedarlane Laboratories, Hornby, ON)
for 2.06 and with R-phycoerythrin-conjugated strep-
tavidin (Jackson ImmunoResearch Laboratories,
West Grove, PA) for Y-17. Afterwards, cells were
washed three times with PBS, ¢xed with 1% para-
formaldehyde and kept on ice under darkness until
assessment of £uorescence by £ow cytometry (Coult-
er Electronics, Epics Elite ESP, Miami, FL).
2.3. Preparation of F(abP)2 fragments
The F(abP)2 fragments of antibody 2.06 were pro-
duced using an Immunopure IgG1 FabP and F(abP)2
preparation kit (Pierce). In brief, the 2.06 antibody
was concentrated with a Centricon-100 (Amicon,
Beverly, MA), resuspended in 0.5 ml of PBS and
added to 0.5 ml of Immunopure IgG1 mild elution
bu¡er containing 1 mM of cysteine. The solution was
then incubated with an immobilized ¢cin column for
40 h at 37‡C. The solution was then eluted with 4 ml
of Immunopure binding bu¡er and fragments were
separated on an Immunopure protein A column. The
column retained Fc fragments and undigested IgG1
whereas F(abP)2 fragments were collected in 1-ml
fractions. Fractions containing F(abP)2 were deter-
mined from absorbance readings at 280 nm and
pooled together. The F(abP)2 fragments (110 kDa)
were then concentrated using Centricon-50 (Amicon)
and resuspended in 1 ml phosphate^EDTA bu¡er
(100 mM sodium phosphate and 5 mM EDTA, pH
6.0).
The F(abP)2 fragments of antibody Y-17 were pro-
duced following incubation of the antibody (7 mg/
ml) with lysyl endopeptidase (in 50 mM Tris^HCl,
pH 8.5) in an enzyme/substrate molar ratio of 1:50
at 37‡C for 3 h. Lysyl endopeptidase cleaved IgG2b
at Lys 228E/Cys 229 without perturbing disul¢de
bridges [16]. The digestion products contained undi-
gested IgG, F(abP)2 and Fc fragments. The enzyme
was removed by gel chromatography on a Sephadex
G-25M column (Pharmacia), and fragments were
fractionated with Protein A a⁄nity chromatography
column (Pharmacia) and resuspended in phosphate^
EDTA. The IgG^F(abP)2 percentage yield was ap-
proximately 30% for both antibodies.
2.4. Preparation of FabP fragments
F(abP)2 fragments were incubated with 6 mg of 2-
mercaptoethylamine^HCl (MEA, ¢nal concentration
of 0.05 M) for 90 min at 37‡C under nitrogen atmo-
sphere. MEA cleaved the disul¢de bridges between
the heavy chains but preserved the disul¢de linkages
between the heavy and light chains. The solution was
eluted on a Sephadex G-25M column pre-equili-
brated with acetate^EDTA bu¡er (100 mM anhy-
drous sodium acetate, 88 mM sodium chloride and
1 mM EDTA, pH 6.5) and FabP fragments were
collected in 1 ml fractions. Fractions containing
FabP were determined using a BCA protein assay
reagent kit (Pierce) and pooled together. The FabP
fragments (55 kD) were concentrated using Centri-
con-10 (Amicon), resuspended in acetate^EDTA
bu¡er (pH 6.5) and kept under nitrogen atmosphere
at 4‡C until coupling to liposomes. The F(abP)2^FabP
percentage yield was approximately 100%. The pu-
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rity of FabP fragments was assessed by SDS^PAGE
and their antigenic speci¢city was veri¢ed by £ow
cytometry on appropriate cells.
2.5. Preparation of immunoliposomes
Liposomes composed of DPPC/DPPG/MPB-
DPPE in a molar ratio of 10:3:0.33 were prepared
according to the method of thin lipid ¢lm hydration.
In brief, the lipid mixture was dissolved in chloro-
form:methanol (2:1 v/v) in a round-bottomed £ask
and the organic solvent was then evaporated to form
a thin lipid ¢lm. In some experiments, [3H]chol-
esterylhexadecylether (0.3 WCi/Wmol lipid) was ad-
ded as radioactive tracer. The lipid ¢lm was then
hydrated with an acetate^EDTA bu¡er (pH 6.5).
Multilamellar vesicles (MLVs) were sequentially ex-
truded through 0.2 Wm and 0.1 Wm polycarbonate
membranes (Nuclepore, Cambridge, MA) using a
stainless-steel extrusion device (Lipex Biomembranes,
Vancouver, BC). Vesicle size distribution and homo-
geneity of the large unilamellar vesicles (LUVs) were
evaluated by quasi-elastic light scattering with a sub-
micron particle analyzer (model N4SD, Coulter Elec-
tronics, Hialeah, FL). The mean vesicle size of the
liposomes was 85 þ 6 nm. The ¢nal concentration of
liposomes was determined using an enzymatic colori-
metric method (phospholipids B kit, Wako Chemi-
cals, Richmond, VA). Conventional liposomes were
prepared as above except that no MPB-DPPE was
incorporated in the lipid composition. In some ex-
periments, liposomes were labeled with the £uores-
cent marker DiI. In brief, liposomes were incubated
with DiI (4 Wg DiI/mg lipid) for 60 min at 50‡C with
agitation. Unencapsulated DiI was removed by cen-
trifugation (300Ug for 15 min at 4‡C) of the liposo-
mal preparation through a coarse Sephadex G-50
column (Pharmacia).
2.6. Coupling reaction
Freshly prepared liposomes were incubated with
freshly prepared FabP fragments (35 Wg FabP/Wmol
lipid) overnight at 4‡C under continuous agitation
and under nitrogen atmosphere. Liposome-bearing
surface-attached antibodies were separated from un-
conjugated FabP fragments by ultracentrifugation
(100 000Ug, two times for 45 min at 4‡C) and im-
munoliposomes were resuspended in PBS. The ¢nal
lipid concentration of immunoliposomes was 35 mM
(Wmol phospholipid/ml). The total amount of FabP
conjugated to liposomes was evaluated with the Coo-
massie protein assay reagent (Pierce). The coupling
e⁄ciency of FabP to liposomes was in the range of
15^20%. The ¢nal amount of FabP conjugated to lip-
osomes, as evaluated with the Coomassie protein as-
say reagent (Pierce), was 5 to 7 Wg/Wmol of lipid. The
schematic diagram of the coupling of FabP fragments
to liposomes is presented in Fig. 1.
2.7. In vitro binding and speci¢city of
immunoliposomes
The binding and speci¢city of conventional lipo-
somes and immunoliposomes were evaluated in
RAJI, HUT-78 and SUP-T1 cells (ATCC) by £ow
cytometry assay. Cells were maintained in complete
culture medium of RPMI 1640 supplemented with
10% fetal bovine serum, 2 mM glutamine, 100 U/
ml penicillin G and 100 Wg/ml streptomycin at
37‡C under a 5% CO2 atmosphere. Cells (5U105
cells/ml) suspended in PBS were incubated with 1.5
Wmol of conventional liposomes or immunolipo-
somes for 30 min on ice or at 37‡C and washed three
times with PBS. DiI-labeled (immuno)liposomes were
incubated with PBS whereas DiI-free (immuno)lipo-
somes were stained with FITC-conjugated goat anti-
mouse IgG at a dilution 1:50. Samples were washed
with PBS and resuspended in 1% paraformaldehyde.
The speci¢city of liposomes for the cells was deter-
mined by £ow cytometry from the £uorescence asso-
ciated to DiI (£uorochrome incorporated into the
lipid membrane) and to FITC (£uorochrome associ-
ated to FabP). The e¡ect of liposomal concentration
on the binding level of immunoliposomes to RAJI
cells has also been evaluated according to the same
protocol described above.
2.8. Tissue distribution
A single bolus injection of conventional liposomes
or immunoliposomes (0.2 Wmol lipid/150 Wl) was ad-
ministered subcutaneously in the upper back below
the neck of female C3H (18^20 g; Charles River
Breeding Laboratories, St-Constant, QC). At speci¢c
times animals were killed, and blood was collected
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and separated by centrifugation (6000Ug for 10 min
at 4‡C). At the same time, tissues (liver, spleen, lung,
thymus, kidney and cervical, brachial, mesenteric,
gluteal and popliteal lymph nodes) were collected,
washed in PBS and weighed. Tissues and plasma
were then treated with Beckman tissue solubilizer
(BTS-450, Beckman Instruments, Irvine, CA) and
decolored in H2O2. Lipid levels in all samples were
monitored by scintillation countings. Six animals
were used for each time point.
2.9. Statistical analysis
All statistical analyses were performed using a
computer package (Statview+SE Software, Abacus
Concepts, Berkeley, CA). The signi¢cance between
groups was statistically evaluated using a one-way
analysis of variance (ANOVA) test, followed by t-
test with Fisher’s corrections.
3. Results
3.1. Enzymatic digestion of antibodies
The purity of IgG1 (clone 2.06) and IgG2b (clone
Y-17) antibodies isolated and puri¢ed from ascites
£uids and of FabP fragments generated from enzy-
matic digestion was con¢rmed by SDS^PAGE (Fig.
2). IgG2b antibodies are known to be highly resistant
to enzymatic digestion. However, lysyl endopeptidase
was very e⁄cient in cleaving the core hinge of IgG2b
without a¡ecting the inter-heavy chain disul¢de
bridges. The enzymatic digestion e⁄ciency of IgG2b
(clone Y-17) into FabP fragments was comparable to
that obtained for IgG1 (clone 2.06) antibody using
the Immunopure IgG1 commercial preparation kit.
The antigenic speci¢city of FabP fragments of 2.06
antibody for Ia antigen of B lymphocytes and of
Y-17 antibody for I-E antigen of C3H mice spleen
cells has also been con¢rmed by £ow cytometry anal-
yses (data not shown).
Fig. 2. SDS^PAGE of IgG1 (clone 2.06) and IgG2b (clone Y-
17) antibodies isolated and puri¢ed from ascites £uids using a
protein-G a⁄nity column and of their FabP fragments obtained
by enzymatic digestion using immobilized ¢cin and lysyl endo-
peptidase, respectively. MW, molecular mass standard.
Fig. 1. Schematic representation of the coupling of FabP fragments to MPB-DPPE liposomes. F(abP)2 fragments of IgG1 and IgG2b
antibodies were obtained by enzymatic digestion using immobilized ¢cin and lysyl endopeptidase, respectively. FabP fragments were
obtained by reduction of F(abP)2 fragments with 2-mercaptoethylamine^HCl. Immunoliposomes were generated following incubation
of FabP fragments with freshly prepared MPB-DPPE liposomes. (Reproduced with permission from [48].)
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3.2. In vitro binding of immunoliposomes
Fig. 3 shows the levels of binding of conventional
liposomes and human anti-HLA-DR (IgG1, clone
2.06) immunoliposomes on three human lymphoma
cell lines expressing di¡erent surface levels of the
human HLA-DR determinant of MHC-II revealed
by £ow cytometry. As expected, anti-HLA-DR im-
munoliposomes did not bind to SUP-T1 cells that do
not express HLA-DR on their surface (Fig. 3A). In
contrast, a high level of binding was observed follow-
ing incubation of liposomes bearing anti-HLA-DR
with both the HUT-78 or RAJI cells (Fig. 3B,C)
which bear signi¢cant levels of human HLA-DR on
their surface. In addition, £ow cytometry scans of
RAJI cells incubated with MPB-PE containing lip-
osomes for 30 min at 37‡C and revealed with a goat-
anti-mouse-FITC-IgG showed that MPB-PE lipo-
somes did not aspeci¢cally bind to cells (data not
shown). These results clearly showed that liposomes
bearing human anti-HLA-DR FabP fragments were
very speci¢c to cells expressing HLA-DR determi-
nant of MHC-II. The speci¢city of murine anti-
HLA-DR immunoliposomes for I-E antigens present
on mouse spleen cells has also been evaluated. In this
case, we could not use a conjugated goat anti-mouse
IgG against mouse spleen cells as non-speci¢c bind-
ing would have occurred. Instead, we have used DiI-
labeled liposomes to determine the speci¢city of im-
munoliposomes and results clearly demonstrated that
liposomes bearing human anti-HLA-DR FabP frag-
ments were speci¢c to cells expressing the HLA-DR
determinant of MHC-II whereas conventional lipo-
somes did not bind to mouse cells (data not shown).
The e¡ect of liposomal concentration on the levels
of binding of human anti-HLA-DR immunolipo-
somes on B lymphocytes has also been investigated
using two di¡erent £uorescent markers: (i) a goat
anti-mouse IgG (FITC) which binds to FabP frag-
ments and (ii) a £uorescent lipophilic DiI marker
incorporated within the lipid membrane of immuno-
Fig. 4. E¡ect of liposomal concentration on the binding level of
human anti-HLA-DR immunoliposomes with B lymphocytes as
revealed by FITC-conjugated goat anti-mouse IgG which binds
to FabP fragments (a) and by a £uorescent lipophilic DiI
marker incorporated within the lipid membrane of immunolipo-
somes (b).
Fig. 3. Flow cytometry scans of (A) SUP-T1, (B) HUT-78 and
(C) RAJI cells incubated with conventional liposomes and lipo-
somes bearing anti-HLA-DR (IgG1, clone 2.06) FabP fragments
for 30 min at 37‡C and revealed with a goat anti-mouse FITC-
IgG. Solid lines, cells incubated with conventional liposomes;
dotted lines, cells incubated with human anti-HLA-DR immu-
noliposomes.
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liposomes. Results showed that the binding level of
immunoliposomes with B cells, when incubated at
37‡C, rapidly saturated when using FITC-conjugated
goat anti-mouse IgG as a marker whereas it in-
creased linearly over the lipid concentration range
when considering the £uorescence signal associated
to DiI (Fig. 4). The saturation e¡ect observed in
the binding level of immunoliposomes using FITC
as a marker is attributed to the fact that a constant
concentration of FITC-IgG was used for all liposo-
mal concentration used. In contrast, as DiI is located
in the lipid bilayer of immunoliposomes, the £uores-
cence intensity level was directly proportional to the
lipid concentration used. Flow cytometry scans of
HUT-78 cells incubated with DiI-labeled convention-
al liposomes as control clearly showed that there was
no transfer of the £uorochrome from liposomes to
cells (data not shown).
The binding level of immunoliposomes with B cells
at 37‡C was similar to that observed 4‡C (data not
Fig. 5. Tissue distribution of conventional liposomes (stippled bar) and anti-HLA-DR (IgG2b, clone Y-17) immunoliposomes (solid
bar) in (A) brachial lymph nodes, (B) cervical lymph nodes, (C) liver and (D) spleen following a single subcutaneous injection to
mice. Values represent the mean ( þ S.E.M.) obtained for six animals per group per time point. *Signi¢cantly di¡erent (P6 0.01) when
compared to conventional liposomes.
Table 1
Area under the curve of anti-HLA-DR immunoliposomes and conventional liposomes in di¡erent tissues following a single subcutane-
ous administration to C3H micea
Tissues Immunoliposomes Conventional Ratio immunoliposomes/conventional liposomes
Cervical lymph nodes 105.04 36.37 2.89
Brachial lymph nodes 61.65 39.20 1.57
Liver 4.03 4.21 0.96
Spleen 3.32 7.65 0.43
aValues, expressed in Wmol lipids/g tissues/h, were calculated from the mean values of the tissue distribution pro¢le using the trapezoi-
dal rule.
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shown). As HLA-DR in an internalizing receptor, a
reduction in £uorescence should have been seen at
37‡C compared to 4‡C since internalization of the
¢rst antibody should impede the binding of the sec-
ond antibody conjugated to FITC. However, since
FACS has been performed in excess antibody con-
centration, it is possible that recycled HLA-DR on
the cell surface, following internalization, is again
available for binding so that the overall £uorescence
levels observed at 4‡C and 37‡C were similar. Data
were presented only for incubation of cells with im-
munoliposomes at 37‡C as they are representative of
the in vivo conditions.
3.3. Lymphoid tissue targeted by liposomes
The accumulation of conventional and murine
anti-HLA-DR immunoliposomes within lymphoid
and non-lymphoid tissues has been investigated fol-
lowing a single subcutaneous injection given in the
upper back of C3H mice. Fig. 5 shows the liposomal
concentration within the cervical lymph nodes, bra-
chial lymph nodes, liver and spleen at di¡erent time
intervals post-injection. Liposomes bearing murine
anti-HLA-DR FabP fragments targeted more e⁄-
ciently the cervical lymph nodes when compared to
that of conventional liposomes with a peak accumu-
lation at 24 h post-injection. The accumulation of
anti-HLA-DR immunoliposomes within brachial
lymph nodes was very similar to that of conventional
liposomes in the ¢rst 12 h post injection but was
signi¢cantly higher at 24 and 48 h post-injection.
No signi¢cant liposomal accumulation was observed
for either type of liposomes in the mesenteric, gluteal
and popliteal lymph nodes as well as in the lung,
thymus and kidney of animals (data not shown).
The concentration of anti-HLA-DR immunolipo-
somes within the liver was signi¢cantly lower than
that of conventional liposomes for the ¢rst 12 h
post-injection but reached similar values at 24 and
48 h post-administration whereas a lower accumula-
tion of immunoliposomes was observed in the spleen
for all time points studied.
Table 1 shows the area under the curve of anti-
HLA-DR immunoliposomes and conventional lipo-
somes in di¡erent tissues. When compared to con-
ventional liposomes, the subcutaneous administra-
tion of anti-HLA-DR immunoliposomes resulted in
a 2.9- and 1.6-times greater accumulation in the cer-
vical and brachial lymph nodes, respectively. On the
other hand, the liposomal accumulation in the liver
was similar for both liposomal preparations, whereas
an approximately twofold decrease in accumulation
was observed for immunoliposomes in the spleen. In
addition, results clearly showed that the subcutane-
ous administration route was very e⁄cient for lymph
node targeting as evidenced by the much higher ac-
cumulation of immunoliposomes in these tissues
when compared to that observed in the liver and
spleen.
4. Discussion
Highly active antiretroviral therapy (HAART) has
been shown to be e¡ective to reduce the plasma viral
load to undetectable levels in HIV-infected individu-
als. However, the capacity of HIV to establish latent
infection of CD4+ T cells allows viral particles to
persist in tissues despite immune responses and anti-
retroviral therapy. Studies have established that rep-
licative-competent HIV-1 are routinely isolated from
resting CD4+ T cells from patients receiving
HAART even after 30 months of therapy [17^21].
In addition, it was recently shown that initiation of
HAART in infected individuals, as early as 10 days
after the onset of symptoms of primary HIV-1 infec-
tion, did not prevent generation of latently infected
resting CD4+ T cells carrying integrated HIV-1
DNA despite the successful control of plasma vire-
mia [22]. On the other hand, increasing numbers of
treatment failures resulting from toxicity, drug-resist-
ant mutants and poor compliance of patient to drug
regimen are emerging with long-term therapy. Taken
together, these results suggest that there is a need to
develop new strategies to increase the concentration
of drugs in lymphoid organs in order to improve the
e⁄cacy and safety of antiretroviral agents. Lipo-
somes bearing surface-attached antibodies directed
speci¢cally against HIV reservoirs represent a con-
venient approach to achieve such as a goal.
One common feature of retroviruses, as well as of
many enveloped viruses, is the acquisition of host cell
surface molecules during the budding process [23^
28]. For example, the human immunode¢ciency vi-
ruses type-1 (HIV-1) and -2 (HIV-2) have been
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shown to incorporate a vast array of cell membrane
derived structures while budding out of the infected
cell. The demonstration that host-derived HLA-DR
proteins are physically present on the virion surface
is of interest for the present study [26,29^38]. The
physiological relevance of cellular HLA-DR bound
on HIV-1 is provided by previous studies from our
laboratory indicating that HLA-DR is one of the
most abundant host-derived molecules carried by
HIV-1 [39^42]. Our in vitro results clearly showed
that liposomes bearing anti-HLA-DR FabP frag-
ments bind speci¢cally to cells expressing surface
HLA-DR, suggesting that a more e⁄cient drug tar-
geting of these cells and of the virus itself could be
achieved using immunoliposomes. Such speci¢c tar-
geting of HIV reservoirs could improve the e⁄cacy
of antivirals and reduce the toxicity associated with
the administration of these drugs.
Among the di¡erent coupling methods of antibod-
ies on liposomes, the use of the bifunctional agent
MPB-PE allowed numerous advantages such as: (i)
covalent linking of FabP fragments with preformed
liposomes, (ii) adequate orientation of the antibody
for maximal accessibility to antigen binding and (iii)
reduction of potential loss of immunoreactivity of
the FabP fragment due to the mild conditions used
during coupling [43]. Proteolytic fragmentation of
murine IgG2b antibodies is known to be highly re-
sistant to enzymatic digestion involving conventional
proteases such as papain or pepsin. In the present
study, lysyl endopeptidase has been used since it
was previously demonstrated to cleave the core hinge
portion of the murine IgG2b without a¡ecting the
inter-chain disul¢de bridges which are needed for
further coupling of FabP fragments with the thiol-
reactive MPB-DPPE lipid [16]. Our results clearly
showed that this enzyme allowed e⁄cient fragmenta-
tion of IgG2b (clone Y-17) antibody and that lipo-
somes having surface attached anti-HLA-DR FabP
fragments were very speci¢c to their antigen in a
dose-dependent manner.
In order to maximize the targeting of anti-HLA-
DR immunoliposomes to the lymph nodes, we have
used liposomes having a mean diameter of 85 nm
and the subcutaneous administration route. The
choice of the size of liposomes is based on previous
demonstration that the passage of liposomes from
the lymphatic vessel fenestration into the lymph
nodes occurs via a maximum liposome size having
a diameter less than 120 nm [12]. In addition, it was
recently shown that the lymphatic uptake from the
subcutaneous site of injection of small liposomes was
high as compared to large liposomes which remained
almost completely at the site of injection [9]. On the
other hand, the subcutaneous administration route
was selected because it represents a convenient ap-
proach to target the lymph nodes. In addition, in
contrast to intravenous administrations of drugs, it
is a simple route for patient self-administration of
liposomal drugs or for the use of subcutaneous
pumps to serve as a depot for the sustained release
of drugs in vivo. This could lead to the generation of
new modes of delivery in the future for the treatment
of HIV.
As expected, tissue distribution experiments
showed that, overall, anti-HLA-DR immunolipo-
somes accumulated better in the cervical and brachial
lymph nodes when compared to conventional lipo-
somes. No signi¢cant liposomal accumulation was
observed for both types of liposomes in the mesen-
teric, gluteal and popliteal lymph nodes of animals.
When injected subcutaneously, liposomes are drained
by the lymph which passes through several lymph
nodes on their way before returning to the thoracic
duct. Consequently, following their administration,
liposomes will ¢rst accumulate within the cervical
lymph nodes which are the nearest lymphoid tissues
from the injection site. Thereafter, if liposomes are
not all retained by these tissues, they continue to
migrate via the lymph to reach the next nearest lym-
phoid tissues which are, in our case, the brachial
lymph nodes. In the same time, because of the rela-
tively small size of liposomes used (85 nm), some of
them could also extravasate through capillaries and
reach the circulation to accumulate within the liver
and spleen. In addition, as liposomes are absorbed
into local lymphatic through gaps between endothe-
lial cells lining lymphatic capillaries before reaching
the bloodstream, the increase of liposomal levels in
liver at longer time points could also be the conse-
quence of the saturation of binding sites in the lymph
nodes. Because of the speci¢c antibody^antigen in-
teraction, a higher concentration of anti-HLA-DR
immunoliposomes accumulated within lymph nodes.
However, a signi¢cant concentration of immunolipo-
somes still reached the spleen, so that the incorpora-
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tion of antiviral agents within this liposomal prepa-
ration should most likely deliver therapeutic levels of
drugs within this HIV reservoir. Furthermore, an
e⁄cient targeting of all lymph nodes could be ob-
tained by delivering subcutaneous liposomal drugs
at di¡erent sites of injection.
The coupling of hydrophilic polyethyleneglycol
(PEG) chains on the surface of liposomes could rep-
resent another attractive approach to target several
important HIV reservoirs including the lymph nodes.
Such sterically stabilized liposomes have been re-
ferred as Stealth liposomes because of their ability
to avoid their rapid uptake by cells of MPS [44,45].
The intravenous administration of PEG-modi¢ed lip-
osomes to mice was shown to reduce the uptake of
liposomes by cells of the MPS and to increase their
accumulation in lymph nodes when compared to
conventional liposomes [46]. In addition, as we
have demonstrated previously, the use of PEG-modi-
¢ed liposomes could result in an accumulation of
liposomes in tissues for much longer periods than
that of conventional liposomes and consequently
prolong the therapeutic e¡ect of the entrapped drug
[47]. Based on the above demonstration, attachment
of antibodies to PEG-modi¢ed liposomes could be a
valuable approach to combine both the speci¢c tar-
geting of lymph nodes while reducing the accumula-
tion of immunoliposomes at the injection site.
The use of liposomes as drug carriers could lead to
the development of innovative approaches that could
improve the targeting of HIV reservoirs. Such tar-
geted delivery system may reduce the dissemination
of HIV from the lymphoid tissues and preserve the
follicular dendritic cells microenvironment that will
likely protect the infected host from developing the
characteristic immunode¢cient state. Moreover, lip-
osomes may allow less frequent administrations of
antiviral agents and at lower doses than conventional
therapy, therefore reducing the marked toxicity ac-
tually seen in patients undergoing antiviral therapy
with free drugs. As protease inhibitors have very
poor oral bioavailability because of their digestion
or binding to gut proteases and their rapid metabo-
lism, their incorporation into liposomes will, most
likely, positively a¡ect their overall e⁄cacy. Liposo-
mal or immunoliposomal drugs, used alone or in
combination, could thus o¡er new alternatives to
the therapy of this deadly disease.
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